An Evanishing Thyroid During Immune Checkpoint Inhibitor Therapy. (22nd March 2022)

• Record Type: Journal Article
• Authors: Cuzzocrea, Marco; Paone, Gaetano; Ceriani, Luca; Giovanella, Luca
• Is Part Of: Clinical nuclear medicine. Volume 47:Number 3(2022)
• Page Start: 253
• Page End: 254
• Publication Date: 2022-03-22
• Subjects: FDG PET/CT -- immune check point inhibitors -- nivolumab -- thyroid -- thyroiditis; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000003946
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract: In recent years, a large number of articles have described the endocrine-related adverse events associated with immune checkpoint inhibitors, especially affecting the thyroid. A 37-year-old man affected by nasopharyngeal carcinoma (stage IVb) underwent serial 18 F-FDG PET/CT evaluations during treatment with nivolumab (480 mg every 4 weeks) after first-line chemoradiotherapy. The patient had no history of thyroid disease and before starting immunotherapy the thyroid-stimulating hormone value was normal at 0.9 mU/L (reference range, 0.27–4.2 mIU/L). FDG PET/CT studies revealed involution of the thyroid gland following immune checkpoint inhibitor–induced thyroiditis.